Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives

Abstract Alzheimer’s disease (AD) is the most common type of dementia. Monoclonal antibodies (MABs) serve as a promising therapeutic approach for AD by selectively targeting key pathogenic factors, such as amyloid-β (Aβ) peptide, tau protein, and neuroinflammation. Specifically, based on their effic...

Full description

Saved in:
Bibliographic Details
Main Authors: Byeong-Hyeon Kim, Sujin Kim, Yunkwon Nam, Yong Ho Park, Seong Min Shin, Minho Moon
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Translational Neurodegeneration
Subjects:
Online Access:https://doi.org/10.1186/s40035-025-00465-w
Tags: Add Tag
No Tags, Be the first to tag this record!